Universal Ibogaine — Fact Sheet (February 2022)

4 slides from Universal Ibogaine's fact sheet, February 2022

Slide 1: Company Overview
UL) (ii) & 3 a 8 © 2 G 2 @ 4 UNIVERSAL IBOGAINE Nick Karos Chief Executive Officer Greg Leavens, CPA, CA Chief Financial Officer Dr. lan Rabb Chief Clinics Officer Hirpal Hundial Director of Clinical Services Colleen Clandening Director, Operations Chief lan Campbell, MBA Chairman (Independent) Dr.
Slide 2: Fully Diluted Share Structure and Addiction Background
In # millions Exercise Price Term Total Shares issued and outstanding at December, 2021 (notes 1) 190.5 Options (brokers and PSQ Directors) $0.10 1 to 2 years 49 Options (UI D & Os) $0.25 5 years 13.8 Performance shares - Directors and CEO n/a n/a 32) (based on clinical trials and other targets) Adv
Slide 3: Why Universal Ibogaine?
Ve hy UNIVERSALIBOGAINE ? Offers an opportunity to help tackle the scourge of addiction. We present an ethical, medically supervised and regulatory- sanctioned channel to participate in the PSYCHEDELICS space Our ibogaine “biotech” play is partially “de-risked” due to the real-world data/evidence ba
Slide 4: Pre-CTA Meeting and Clinical Milestones Timeline
--2021-- Q4 Pre-CTA Meeting CTA Submission NOL, Ph2/HPOC Initiation* *Human proof of concept study (usually aligned with a ph28 (phase) development stage) --2022-- Q4 (Onward) Ph2/HPOC Completion Ph2/HPOC Readout Special Access (or Ph3/pivotal Start) Pre-CTAY Meeting Clinic 3+ Licensing / Franchisin